Autologous Stem Cell Transplantation

3

Review clinical trials related to Autologous Stem Cell Transplantation. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

CIBMTR Research Database

The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies. A secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries. Objectives: To learn more about what makes stem cell transplants and cellular therapies work well such as: * Determine how well recipients recover from their transplants or cellular therapy; * Determine how recovery after a transplant or cellular therapy can be improved; * Determine how a donor's or recipient's genetics impact recipient recovery after a transplant or cellular therapy; * Determine how access to transplant or cellular therapy for different groups of patients can be improved; * Determine how well donors recover from the collection procedures.

Participants needed: 99,999,999
Trial details
Biological sex: AllType: ObservationalSponsor: Center for International Blood and Marrow Transplant ResearchUpdated: Aug 12, 2025Locations: 2
Eligibility criteria

Any recipient of an unrelated or related donor or autologous HSC transplant in a... [+3]

Status: Recruiting

Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan

Patients who receive a chemotherapy called melphalan are at high risk of having nausea and vomiting. A medication called olanzapine has been shown to decrease nausea and vomiting after chemotherapy. A previous research study found the 10 mg dose of olanzapine (combined with 3 standard medications used routinely to prevent nausea/vomiting) to be effective for patients who received melphalan chemotherapy, but several other studies have shown many patients have a side effect of sleepiness (e.g., sedation) with that dose of the medication. Our study will compare two lower doses of olanzapine (5 mg and 2.5 mg) in combination with the 3 standard medications used to prevent nausea/vomiting in the patients who receive melphalan chemotherapy to determine which dose is effective in preventing nausea and vomiting with the lowest amount of sleepiness side effect.

Participants needed: 172
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Augusta UniversityUpdated: Nov 22, 2024Locations: 1
Eligibility criteria

Receipt of high-dose melphalan 140-200 mg/m2 [+1]

Allergy to olanzapine [+5]

Status: Recruiting

Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

The primary purpose of the Research Sample Repository is to make blood samples available for research studies related to histocompatibility and hematopoietic cell transplantation (HCT) or other cellular therapy. Representatives of participating centers and investigators or research groups may request access to research samples contained in the Research Sample Repository for the purpose of conducting research including: * investigating molecular explanations for histocompatibility or clinical outcomes through analysis of genomic, epigenetic, or other biomolecular data * evaluating the factors that affect transplant or cellular therapy outcome * studying the distribution of HLA tissue types in different populations * studying the success of transplantation, cellular therapies or supportive care in the management of marrow toxic injuries * performing de-linked (anonymous) research

Participants needed: 99,999,999
Trial details
Biological sex: AllType: ObservationalSponsor: Center for International Blood and Marrow Transplant ResearchUpdated: May 3, 2023Locations: 1
Eligibility criteria

Donors are eligible to participate in the Research Sample Repository if they hav... [+5]